Multicenter clinical studies of recombinant human Brain Natriuretic Peptide (XinHuosu) in Emergency Department in patients with Acute Left Heart Failure

Multicenter clinical studies of recombinant human Brain Natriuretic Peptide in Emergency Department in patients with Acute Left Heart Failure

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-13003823

Enrollment

Unknown

Registered

2013-11-14

Start date

2011-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute left heart failure

Interventions

trial group:Standard treatment+rhBNP

Eligibility

Sex/Gender

All

Age

27 Years to 96 Years

Inclusion criteria

Inclusion criteria: 1. Acute decompensated heart failure, regardless of etiology; 2. Acute exacerbation of chronic heart failure or Refractory refractory heart failure.

Exclusion criteria

Exclusion criteria: 1. hypotension (SBP<90mmHg); 2. Cardiogenic shock; 3. Cardiopulmonary arrest; 4. Low cardiac output; 5. Psychological disorders; 6.ACS; 7. Pulmonary embolism; 8. ESRD; 9. Contraindications associated with nitroglycerin or intravenous vasodilator clinical status; 10. Ventricular tachycardia; 11. Allergy for recombinant human brain natriuretic peptide; 12. NT-proBNP levels were normal; 13. Pregnant or planning to become pregnant, and lactating women; 14. Participation in other clinical trials.

Design outcomes

Primary

Measure	Time frame
NT-ProBNP;Vital Sign (HR, BP, T);24 hour urine volume;Biochemical Indicator (liver function, SCr, Bun, CK-MB, TroponinT/I);ECG;echocardiography;Clinical sign;	—

Countries

China

Contacts

Public ContactChunsheng Li

Emergency Department, Main Campus, Beijing Chao-Yang Hospital

lcscyyy@sohu.com+86 010-85231000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026